DSIP (Delta Sleep-Inducing Peptide): Structure and Research History

Delta sleep-inducing peptide, almost always shortened to DSIP, is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was isolated in the 1970s and named after the experimental setting in which it was found, yet nearly five decades later its precursor gene, its receptor and its physiological role remain unidentified. For researchers, the dsip peptide is therefore as much a lesson in the history and methodology of peptide discovery as it is a compound with a defined mechanism.

This profile describes how DSIP was discovered, what its structure and chemistry look like, why its biology has proved so difficult to pin down, and what that means for anyone designing experiments with it. Synthetic material such as the DSIP research peptide is supplied for laboratory research use only; not for human or veterinary use.

Discovery and the origin of the name

DSIP was reported in 1977 by Guido Schoenenberger and Marcel Monnier in Basel. Their approach was physiological rather than genetic. Rabbits were placed in a state of slow-wave, delta-dominated electroencephalogram (EEG) activity by low-frequency electrical stimulation of the thalamus, and cerebral venous blood was collected. A dialysate of that blood was fractionated and tested in recipient rabbits, where some fractions increased delta-band EEG activity. Purification of the active fraction yielded a nonapeptide, which was then sequenced and synthesised.

The name therefore describes the bioassay used to find the peptide, not a demonstrated physiological function. That distinction matters because the name has shaped expectations of the compound for decades, while later work produced inconsistent results. These were animal experiments using EEG readouts in the 1970s, with the methodological limits of that era, and they should be read as historical preclinical observations.

Structure and chemistry

DSIP has the sequence H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH. It contains only L-amino acids, has free termini, and carries no disulfide bonds or other modifications. The molecular formula is C₃₅H₄₈N₁₀O₁₅ and the average molecular weight is approximately 848.8 g/mol.

Several features stand out. Three of the nine residues are glycine, which makes the backbone very flexible, and spectroscopic studies have generally found that DSIP has little stable secondary structure in aqueous solution. With Asp, Glu and the C-terminal carboxyl against a single N-terminal amine, the peptide carries a net negative charge near neutral pH and is highly water-soluble. The N-terminal tryptophan gives useful UV absorbance at 280 nm and is the main chemical liability, being prone to oxidation. A phosphorylated form with phosphoserine at position 7 has also been described in the literature and is sometimes discussed as a possible natural variant.

Stability in biological media

Like most short, unmodified linear sequences in a general catalogue of research peptides, DSIP has a free N-terminus and is a substrate for aminopeptidases and other peptidases. For the same reason, size- and charge-matched peptides from such a range can serve as additional negative controls when stability is compared side by side. In vitro incubations in blood and tissue preparations have shown fairly rapid degradation, with cleavage at the N-terminal Trp-Ala bond reported as a major route. This is a practical issue for any assay in serum-containing media, and the general principles are covered in our article on peptidases and peptide degradation.

An unresolved biology

No gene, no receptor

Most peptide hormones are traced back to a precursor protein encoded by a known gene, and their actions to a specific receptor. DSIP has neither. No gene encoding a DSIP precursor has been convincingly identified, and no receptor with high affinity and selectivity for DSIP has been cloned. DSIP-like immunoreactivity has been reported in the hypothalamus, pituitary and a range of peripheral tissues, but immunoassay results depend heavily on antibody specificity. One illustration of the problem is that a protein later characterised as glucocorticoid-induced leucine zipper (GILZ, gene TSC22D3) was initially catalogued under a name referring to DSIP immunoreactivity, despite having no sequence relationship to the nonapeptide itself.

Inconsistent findings

Over the 1980s and 1990s a large number of animal and in vitro studies reported diverse activities for DSIP, involving EEG patterns, stress-related hormones, body temperature and neurotransmitter systems. Reviews of this literature, from Graf and Kastin in the 1980s to Kovalzon and Strekalova in 2006, consistently note that results often failed to replicate, that effects were frequently small or dependent on time of day and experimental conditions, and that the mechanism remained obscure. Kovalzon and Strekalova described DSIP as a still unresolved riddle, which remains a fair summary. All of these were preclinical studies, and the balance of evidence does not establish any single defined function.

Designing experiments with DSIP

Given that background, good experimental design is especially important. Because no receptor is known, there is no validated target-engagement assay, so studies tend to rely on downstream readouts that are prone to nonspecific effects. Useful safeguards include a scrambled-sequence peptide of identical composition as a negative control, vehicle controls matched for counter-ion and pH, and verification by LC-MS that intact DSIP remains present for the duration of the experiment. Where antibody-based detection is used, specificity should be demonstrated against synthetic DSIP and against the scrambled control. Our guide to experimental controls in peptide research covers these choices in more depth.

Analytical and handling notes

Identity is confirmed by mass spectrometry against the expected mass of about 848.8 Da. Tryptophan oxidation products appear at +16 and +32 Da, and N-formylkynurenine and kynurenine species may also be seen in degraded material. The Asp-Ala sequence can undergo isomerisation through a succinimide intermediate, which leaves mass unchanged but may produce a closely eluting HPLC peak, so purity methods should be capable of resolving such isomers. Purity is reported from reversed-phase HPLC at 214 or 220 nm, with 280 nm useful as a secondary check for tryptophan-containing impurities.

Lyophilised DSIP should be stored frozen, dry and protected from light. Solutions are best prepared in a defined buffer, aliquoted and frozen once, and their stability in the actual assay medium measured rather than assumed. When sourcing synthetic DSIP peptide (WAGGDASGE), check that the lot certificate of analysis reports mass spectrometric identity, HPLC purity and counter-ion content.

DSIP as a case study

DSIP is chemically simple and analytically straightforward, but biologically it remains one of the more puzzling peptides in the literature. Its name records an experimental context from 1977 rather than an established function, and the absence of a known gene or receptor means that published findings are difficult to interpret and compare. For a modern laboratory, it is best approached with rigorous controls, verified material and a clear-eyed reading of the preclinical record.

References

1. Schoenenberger, G. A. and Monnier, M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences USA, 1977.
2. Graf, M. V. and Kastin, A. J. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience and Biobehavioral Reviews, 1984.
3. Kovalzon, V. M. and Strekalova, T. V. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 2006.
4. Geiger, T. and Clarke, S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Journal of Biological Chemistry, 1987.